128 related articles for article (PubMed ID: 22374735)
41. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 2nd communication: tissue levels and enzyme activity in rats after repeated administration, and placental and milk transfer after single administration.
Nakamura A; Hirota T; Sugihara K; Watanabe S; Tougou K; Morino A; Ezumi Y; Takaichi M
Arzneimittelforschung; 1997 Feb; 47(2):160-8. PubMed ID: 9079235
[TBL] [Abstract][Full Text] [Related]
43. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
Iwai M; Minematsu T; Li Q; Iwatsubo T; Usui T
Drug Metab Dispos; 2011 Dec; 39(12):2314-20. PubMed ID: 21918035
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of 4-acetylaminophenylacetic acid. 2nd communication: tissue accumulation and enzyme induction in rats after repeated administration, and placental and milk transfer after single dosing.
Sugihara K; Morino A; Sugiyama M; Iida S; Nomura A
Arzneimittelforschung; 1990 Jul; 40(7):806-10. PubMed ID: 2222557
[TBL] [Abstract][Full Text] [Related]
45. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
47. Transplacental and mammary passage of radioactivity in rats treated vaginally and orally with [14C]propranolol.
Buttar HS; Moffatt JH; Bura C
J Toxicol Environ Health; 1988; 24(1):1-18. PubMed ID: 3373560
[TBL] [Abstract][Full Text] [Related]
48. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
49. Mass balance and pharmacokinetics of an oral dose of
Dai X; Karol MD; Hitron M; Hard ML; Blanchard JE; Eraut NCJE; Rich N; Gufford BT
Pharmacol Res Perspect; 2021 Feb; 9(1):e00722. PubMed ID: 33576192
[TBL] [Abstract][Full Text] [Related]
50. Distribution, Metabolism, and Excretion of Cenobamate in Adult, Fetal, Neonatal, and Lactating Rats.
Palamanda J; Glenn KJ; Melnick SM
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):7-21. PubMed ID: 37921950
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
Aoyama Y; Kaibara A; Takada A; Nishimura T; Katashima M; Sawamoto T
Invest New Drugs; 2013 Apr; 31(2):443-51. PubMed ID: 22892872
[TBL] [Abstract][Full Text] [Related]
52. Placental transfer and pharmacokinetics of a single oral dose of [14C]p-nitrophenol in rats.
Abu-Qare AW; Brownie CF; Abou-Donia MB
Arch Toxicol; 2000 Sep; 74(7):388-96. PubMed ID: 11043494
[TBL] [Abstract][Full Text] [Related]
53. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
54. Mammary excretion and placental transfer of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in rats.
Cho YB; Kim KH; Kim DK; Miyamoto G
Arzneimittelforschung; 1996 Sep; 46(9):926-30. PubMed ID: 8876944
[TBL] [Abstract][Full Text] [Related]
55. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
56. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
58. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
[TBL] [Abstract][Full Text] [Related]
59. Disposition of low doses of 14C-bisphenol A in male, female, pregnant, fetal, and neonatal rats.
Kurebayashi H; Nagatsuka S; Nemoto H; Noguchi H; Ohno Y
Arch Toxicol; 2005 May; 79(5):243-52. PubMed ID: 15902421
[TBL] [Abstract][Full Text] [Related]
60. Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-alpha] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys.
Kitagawa H; Esumi Y; Kurosawa S; Sekine S; Yokoshima T
Xenobiotica; 1979 Jul; 9(7):415-28. PubMed ID: 40350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
